CorMedix announces $128.6 million of net revenue for the fourth quarter of 2025, largely driven by continued utilization of DefenCath by its outpatient dialysis customers. DefenCath sales contributed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results